Abstract-In the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (nϭ6632), eplerenone-associated reduction in all-cause mortality was significantly greater in those with a history of hypertension (Hx-HTN Key Words: eplerenone Ⅲ hypertension Ⅲ myocardial infarction Ⅲ heart failure Ⅲ morbidity Ⅲ mortality I n the Eplerenone Post-acute myocardial infarction Heart failure Efficacy and SUrvival Study (EPHESUS), eplerenone, a selective aldosterone blocker, significantly reduced all-cause mortality and the coprimary combined end points of cardiovascular (CV) hospitalization or CV mortality. 1 A subgroup analysis of the EPHESUS suggested that the effect of eplerenone on all-cause mortality was greater in patients with a history of hypertension (Hx-HTN) than in those without Hx-HTN (P for interactionϭ0.05). 1 However, there was no significant difference between these groups for eplerenone on the coprimary combined end points of CV hospitalization or CV mortality. To gain further insight into this relationship, we examined the effects of eplerenone on mortality and morbidity in a propensity score-matched cohort of patients with and without Hx-HTN.
I
n the Eplerenone Post-acute myocardial infarction Heart failure Efficacy and SUrvival Study (EPHESUS), eplerenone, a selective aldosterone blocker, significantly reduced all-cause mortality and the coprimary combined end points of cardiovascular (CV) hospitalization or CV mortality. 1 A subgroup analysis of the EPHESUS suggested that the effect of eplerenone on all-cause mortality was greater in patients with a history of hypertension (Hx-HTN) than in those without Hx-HTN (P for interactionϭ0.05). 1 However, there was no significant difference between these groups for eplerenone on the coprimary combined end points of CV hospitalization or CV mortality. To gain further insight into this relationship, we examined the effects of eplerenone on mortality and morbidity in a propensity score-matched cohort of patients with and without Hx-HTN.
Methods

Study Design and Patients
EPHESUS was a multicenter, international, randomized, doubleblind, placebo-controlled clinical trial of eplerenone. 1 Briefly, 6632 patients with acute myocardial infarction (AMI) complicated by low (Յ40%) left ventricular ejection fraction (LVEF) and symptomatic heart failure (HF) were randomly assigned within 3 to 14 days of their AMI to receive eplerenone 25 mg/d titrated to 50 mg/d (nϭ3319) or matching placebo (nϭ3313). Patients were receiving standard medical therapy, including an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker (87%) and a ␤-blocker. Patients were followed for up to 2.5 years, with a mean follow-up of 16 months. Patients in the placebo and eplerenone groups were receiving a mean dose of 43.5 mg and 42.6 mg per day, respectively. Exclusion criteria included the use of potassiumsparing diuretics, a serum creatinine concentration Ͼ2.5 mg/dL (220 mol/L), and a serum potassium concentration Ͼ5.0 mEq/L (mmol/L). Of the EPHESUS participants, 4007 patients had a history of hypertension (Hx-HTN), and 2625 had no Hx-HTN at the time of enrollment. Of the 4007 patients with Hx-HTN, 2024 (50.5%) were in the placebo group, and 1983 (49.5%) were in the eplerenone group. Of the 2625 patients without Hx-HTN, 1289 (49.1%) were in the placebo group, and 1336 (50.9%) were in the eplerenone group.
The 2 primary end points of the EPHESUS, all-cause mortality and the combined end point of CV hospitalization or CV mortality, were also the primary end points for this analysis. Major secondary end points from EPHESUS, such as CV mortality, which included mortality because of AMI, HF, stroke, and sudden cardiac death (SCD), as well as hospitalization because of AMI and HF, were also studied. The cause of death or the primary diagnosis leading to hospitalization was adjudicated by a blinded EPHESUS critical events committee.
Statistical Analysis
Because the balance achieved by randomization in the main trial may have been lost in the groups with and without Hx-HTN, propensity scores for the receipt of eplerenone were used to assemble a balanced cohort. The propensity score for the receipt of eplerenone for a patient is defined as the conditional probability of receiving eplerenone given that patient's measured covariates. [2] [3] [4] [5] [6] Propensity scores were calculated separately for each of the 4007 and 2625 patients with and without Hx-HTN, respectively, using a nonparsimonious multivariable logistic regression model, incorporating the 36 baseline covariates (Table 1) . Patients receiving eplerenone and placebo were matched based on their propensity to receive eplerenone. In all, 1838 pairs of patients with Hx-HTN and 1176 pairs of patients without Hx-HTN were matched. Absolute standardized differences were estimated to assess residual balance after matching. 6, 7 We used Kaplan-Meier plots and matched Cox regression analysis to estimate the effect of eplerenone in patients with and without Hx-HTN. We used multivariable Cox regression analyses in the prematch cohort, separately adjusting for the raw propensity scores. All of the analyses were based on intent to treat. All of the statistical tests were evaluated using 2-tailed 95% CIs.
Because the sample size of matched patients with Hx-HTN (nϭ3676) was larger than matched patients without Hx-HTN (nϭ2352), we conducted a sensitivity analysis by repeating our analysis in a smaller group of patients with Hx-HTN. In addition, we conducted a sensitivity analysis to determine the potential effects of an unmeasured covariate that may potentially invalidate our main conclusions. 6, 8, 9 
Results
Study Patients
Baseline characteristics of patients with and without Hx-HTN are presented in Table 1 . In both groups with and without Hx-HTN, the distribution of all of the measured baseline covariates was balanced, and there were no statistically significant differences between treatment groups.
Eplerenone and All-Cause Mortality
During a median follow-up of 16 Figure 1A and Table 2 ). Among patients without Hx-HTN, all-cause mortality occurred in 14.4% of the placebo group and 14.2% of the eplerenone group (HR: 0.91; 95% CI: 0.72 to 1.15; Pϭ0.435; Figure 1B and Table 2 ).
Eplerenone and CV Hospitalization or CV Mortality
Among patients with Hx-HTN, the coprimary combined end points of CV hospitalization or CV mortality occurred in 32.8% patients in the placebo group and 28.2% of patients in the eplerenone group (HR: 0.82; 95% CI: 0.72 to 0.94; Pϭ0.003; Figure 2A and Table 2 ). Among patients without Hx-HTN, the coprimary combined end points of CV hospitalization or CV mortality occurred in 25.3% of patients in the placebo group and 23.6% of patients in the eplerenone group (HR: 0.91; 95% CI: 0.76 to 1.10; Pϭ0.331; Figure 2B and Table 2 ).
Eplerenone, SCD, and Other Secondary Study End Points
SCD occurred in 6.5% of patients with Hx-HTN in the placebo group and 5.0% of patients with Hx-HTN in the eplerenone group ( Figure 3A and Table 2 ). Among patients without Hx-HTN, SCD occurred in 5.2% patients in the placebo group and 4.4% patients in the eplerenone group ( Figure 3B and Table 2 ). Effects of eplerenone on other secondary end points in patients with and without Hx-HTN are displayed in Table 2 .
Eplerenone and Adverse Events
In patients with Hx-HTN, the incidence of severe hyperkalemia was significantly higher in patients receiving eplerenone (5.9% versus 4.2%; odds ratio for patients receiving eplerenone: 1.43; 95% CI: 1.06 to 1.93; Pϭ0.019; Table 3 ). The incidence of severe hypokalemia was lower in patients receiving eplerenone (14.7% versus 9.6%; odds ratio for patients receiving eplerenone: 0.62; 95% CI: 0.51 to 0.76; PϽ0.0001). Other adverse events are displayed in Table 3 .
Eplerenone, History of Hypertension, and Baseline Blood Pressure
Eplerenone had a favorable effect on outcomes in patients with Hx-HTN regardless of their baseline systolic blood pressure (SBP). In the subgroups of patients with Hx-HTN and a baseline SBP of Յ120 mm Hg, all-cause mortality occurred in 191 placebo patients (rate: 1465/10 000 personyears) and 157 eplerenone patients (rate: 1176/10,000 personyears; HR: 0.80; 95% CI: 0.65 to 0.99; Pϭ0.043). Eplerenone also reduced CV hospitalization or CV mortality (HR: 0.86; 95% CI: 0.73 to 0.997; Pϭ0.046) in these patients. In Hx-HTN patients with a baseline SBP of Ͼ120 mm Hg, similarly, eplerenone reduced both all-cause mortality (HR: 0.68; 95% CI: 0.52 to 0.87; Pϭ0.002) and the coprimary composite end point (HR: 0.79; 95% CI: 0.66 to 0.94; Pϭ0.010).
Eplerenone and Changes in Baseline Blood Pressure
Increases in SBP from baseline (Table 1) were similar in both groups of patients with or without Hx-HTN and were slightly greater in the placebo group. The SBP increased by 6 and 3 mm Hg in the placebo and eplerenone patients, respectively, in both groups with and without Hx-HTN. Pϭ0.0002) and decreased rates of CV hospitalization or CV mortality (zϭ2.92; Pϭ0.0035). Sensitivity analyses suggest that an unmeasured binary covariate would need to increase the odds of eplerenone use by Ͼ17.6% to explain the all-cause mortality association and by Ͼ6.6% to explain the association with the coprimary end points.
Results of Sensitivity Analyses
Discussion
The results of this analysis demonstrate that the use of eplerenone in patients with Hx-HTN within 3 to 14 days of an AMI, complicated by reduced LVEF and symptomatic HF, was associated with significant reductions in all-cause mortality and the coprimary end points of CV hospitalization or CV mortality. In addition, the use of eplerenone was associated with a significant reduction in SCD in these patients. Although the direction of change with eplerenone in the subgroup of patients without Hx-HTN was similar, significant reductions in these end points were not observed in this subgroup; however, in patients without Hx-HTN, eplerenone significantly reduced hospitalization for HF, suggesting a long-term effect on ventricular remodeling. Although approximately two thirds of patients in EPHESUS had Hx-HTN, their mean blood pressure at the time of random assignment post-AMI was within normal limits. There are several plausible explanations for the differential benefit of eplerenone in patients with Hx-HTN. Effects of a treatment on outcomes are known to vary between groups of patients based on differences in pathophysiology, natural history, severity of disease, comorbidity, and absolute risks between groups. 10 EPHESUS patients with Hx-HTN were older and had more severe disease and comorbidity burden than those without Hx-HTN. They had 14% greater risk for all-cause mortality and 28% increased risk for CV mortality or CV hospitalizations than those without Hx-HTN. Patho- 
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physiologically, compared with patients without Hx-HTN, those with Hx-HTN are at an increased risk of incident AMI, subsequent ventricular remodeling, and CV mortality. [11] [12] [13] [14] Hypertension predisposes patients to an increase in reactive oxygen species, vascular remodeling, and myocardial collagen formation. [15] [16] [17] [18] After AMI, patients with Hx-HTN have been found to have a greater degree of ventricular remodeling than those without Hx-HTN. 13, 19, 20 Ventricular remodeling results in myocardial stretch, which is an important stimulus for activation of various neurohormones, including angiotensin II and aldosterone. 21, 22 HF is associated with an upregulation of mineralocorticoid receptors and aldosterone with an increase in myocardial calcium channel expression. [23] [24] [25] [26] Recently, AMI has been shown to cause electric remodeling before mechanical remodeling and LV hypertrophy. 27 The increase in intracellular calcium associated with electric remodeling has been suggested to increase the risk of ventricular arrhythmias and SCD. 28, 29 Alterations in intracellular calcium and potassium may be greater in patients with AMI and Hx-HTN, many of whom have LV hypertrophy, and an increase in mineralocorticoid receptors and calcium channel expression. 25, 26 Therefore, the effectiveness of eplerenone in patients with Hx-HTN, most of whom were treated with an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker and a ␤-adrenergic receptor blocker, in reducing total mortality and SCD along with a trend toward a reduction in death because of progressive HF can be explained by the effects of aldosterone blockade in preventing electric remodeling, as well as by improving sympathetic/ parasympathetic balance related to a decrease in reactive oxygen species production and an improvement in NO availability. 30 -33 These effects are in addition to the effects of *Data are for all of the cardiovascular adverse events reported, whether they were related to a study end point. †Data are based on investigators' reports. ‡PϽ0.05 indicates a significant difference between patients with and without Hx-HTN. §Among patients with Hx-HTN, 1200 men were in the placebo group and 1208 men were in the eplerenone group. Among those without Hx-HTN, 925 men were in the placebo group and 931 men were in the eplerenone group.
Among patients with Hx-HTN, 633 women were in the placebo group and 621 women were in the eplerenone group. Among patients without Hx-HTN, 245 women were in the placebo group and 244 women were in the eplerenone group. ¶Data are based on laboratory measurements. Data were available for 3622 patients with Hx-HTN (1833 patients, placebo group; 1829 patients, eplerenone group) and 2345 patients without Hx-HTN (1170 patients, placebo group; 1175 patients, eplerenone group).
eplerenone on ventricular mechanical remodeling, LV hypertrophy, and collagen formation, all of which are likely of greater magnitude in those with Hx-HTN. 34 -38 Results of our subgroup analysis suggest that the effects of eplerenone were observed regardless of baseline SBP, suggesting a long-term effect of HTN on target organs rather than baseline blood pressure levels as the underlying mechanistic explanation for the differential effect of eplerenone in the group with Hx-HTN. Another plausible explanation of a differential benefit of eplerenone in patients with Hx-HTN is the larger sample of these patients; however, sensitivity analysis suggests that eplerenone was beneficial in a smaller subset of patients with Hx-HTN. In addition, statistical analysis showed no significant difference in the treatment effect of eplerenone on SBP between patients with and without Hx-HTN, suggesting that our findings were not driven by higher absolute reductions in SBP among patients with Hx-HTN.
This analysis suggests that patients with AMI complicated by a low LVEF and symptomatic HF should be risk-stratified based on Hx-HTN. Those with Hx-HTN should be prescribed eplerenone to improve outcomes. Although we did not observe a significant effect of eplerenone on mortality in patients without Hx-HTN, we did observe a significant reduction in HF hospitalization, likely mediated by a reduction in ventricular remodeling. There was a trend toward a reduction in mortality, but analysis of this subgroup may have been underpowered to detect a significant difference in mortality and other outcomes, which is not surprising given the low baseline risk in these patients. 11 Reduction in HF hospitalization would suggest a long-term effect of eplerenone on mortality in these patients.
Eplerenone was well tolerated in patients with and without Hx-HTN. Although more patients receiving eplerenone experienced hyperkalemia (Ͼ6 mEq/L), overall absolute rates were low, and no deaths were attributed to hyperkalemia in patients receiving eplerenone. Patients receiving eplerenone had a lower risk of developing hypokalemia (Ͻ3.5 mEq/L). This is important, because the overall absolute rate of hypokalemia was higher than that of hyperkalemia, which has been associated with increased mortality. 39 -42 
Perspectives
This analysis suggests that patients with AMI, reduced LVEF, and symptomatic HF should be risk stratified based on their Hx-HTN; and those with Hx-HTN should be treated early post-AMI with eplerenone to prevent death, especially SCD. Because HF hospitalization is an important predictor of CV death and eplerenone reduced HF hospitalization in patients without Hx-HTN, eplerenone should also be initiated in these patients.
